

# Anne J Novak

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6178044/anne-j-novak-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120  
papers

3,743  
citations

27  
h-index

61  
g-index

125  
ext. papers

4,567  
ext. citations

4.7  
avg, IF

4.41  
L-index

#	Paper	IF	Citations
120	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 3879-84	11.5	735
119	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , <b>2018</b> , 24, 679-690	50.5	659
118	Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. <i>Blood</i> , <b>2004</b> , 103, 689-94	2.2	400
117	Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. <i>Blood</i> , <b>2002</b> , 100, 2973-9	2.2	201
116	Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. <i>Blood</i> , <b>2004</b> , 104, 2247-53	2.2	193
115	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. <i>Blood</i> , <b>2007</b> , 110, 2537-44	2.2	151
114	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , <b>2014</b> , 46, 1233-8	36.3	108
113	Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma. <i>Oncotarget</i> , <b>2017</b> , 8, 61425-61439	3.3	83
112	Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 983-7	2.2	76
111	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. <i>American Journal of Human Genetics</i> , <b>2014</b> , 95, 462-71	11	74
110	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 2569-79	16.6	73
109	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , <b>2016</b> , 7, 10933	17.4	70
108	Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2862-72	12.9	68
107	Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. <i>Blood</i> , <b>2011</b> , 118, 5540-9	2.2	58
106	Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. <i>Cancer Research</i> , <b>2009</b> , 69, 4217-24	10.1	48
105	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 187-194	7.1	45
104	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , <b>2015</b> , 6, 5751	17.4	44

103	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. <i>Blood</i> , <b>2009</b> , 113, 5206-16	2.2	40
102	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. <i>Cell Reports</i> , <b>2019</b> , 26, 2178-2193.e3	10.6	37
101	Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. <i>Blood</i> , <b>2011</b> , 117, e190-7	2.2	36
100	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , <b>2014</b> , 30, 2678-80	7.2	35
99	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1753-1754	7.8	35
98	TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5217-5231	12.9	33
97	IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2012</b> , 120, 3774-82	2.2	33
96	Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 865-9	7.1	31
95	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 22	7	28
94	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. <i>Blood Advances</i> , <b>2018</b> , 2, 1985-1997	7.8	27
93	Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 394-403	4.5	23
92	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , <b>2014</b> , 30, 3414-6	7.2	21
91	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 73	7	19
90	Impact of MYD88 mutation status on histological transformation of Waldenstrom Macroglobulinemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 274-281	7.1	18
89	First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , <b>2016</b> , 127, 2936-8	2.2	16
88	SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 84	7	16
87	Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 97	7	16
86	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , <b>2019</b> , 43, 844-863	2.6	15

85	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 644-653	4.5	15
84	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 752-758	7.1	11
83	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000187	4.6	10
82	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 658-666	7.1	9
81	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , <b>2021</b> , 35, 522-533	10.7	9
80	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , <b>2018</b> , 9, 4182	17.4	8
79	First report of MYD88 somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 42-43	2.7	7
78	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 121-121	2.2	7
77	Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. <i>Redox Biology</i> , <b>2020</b> , 36, 101657	11.3	7
76	FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , <b>2017</b> , 35, 447-455	1.3	6
75	B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1884-92	1.9	6
74	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1061-70	4	5
73	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 130	7	5
72	Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1-4	1.9	4
71	The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression. <i>Blood</i> , <b>2015</b> , 126, 2661-2661	2.2	4
70	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 117	7	4
69	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. <i>Blood</i> , <b>2005</b> , 106, 2411-2411	2.2	3
68	Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.. <i>Blood</i> , <b>2008</b> , 112, 2251-2251	2.2	3

67	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , <b>2012</b> , 120, 2699-2699	2.2	3
66	Chronic lymphocytic leukemia B-cell-derived TNF $\alpha$ impairs bone marrow myelopoiesis. <i>Science</i> , <b>2021</b> , 24, 101994	6.1	3
65	Interactions Between PD-1 and PD-L1 and PD-L2 Promote Malignant B-Cell Growth in Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2013</b> , 122, 4334-4334	2.2	2
64	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5759-5771	12.9	2
63	Role of B-Lymphocyte Stimulator (BLyS) in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2005</b> , 106, 601-601	2.2	1
62	Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.. <i>Blood</i> , <b>2006</b> , 108, 2722-2722	2.2	1
61	Altered Expression of Immune Checkpoint Molecules Including Programmed Cell Death-1 (PD-1) and Its Ligands PD-L1/PD-L2 in Waldenstrom's Macroglobulinemia. <i>Blood</i> , <b>2016</b> , 128, 1772-1772	2.2	1
60	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , <b>2016</b> , 128, 5299-5299	2.2	1
59	Non-Hodgkin Lymphoma B-Cells Induce Intratumoral CD4+CD25 $^+$ T Cells To Express Foxp3 and Gain Regulatory Function.. <i>Blood</i> , <b>2006</b> , 108, 1724-1724	2.2	1
58	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2018</b> , 132, 2884-2884	2.2	1
57	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 603-603	2.2	1
56	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 925-925	2.2	1
55	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 3933-3933	2.2	1
54	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , <b>2013</b> , 122, 499-499	2.2	1
53	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , <b>2013</b> , 122, 76-76	2.2	1
52	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.. <i>Blood</i> , <b>2007</b> , 110, 3585-3585	2.2	0
51	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2018</b> , 132, 4141-4141	2.2	0
50	Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2009</b> , 114, 1691-1691	2.2	0

49	TGF- $\beta$ s Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , <b>2011</b> , 118, 1586-1586	2.2	○
48	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 308-315	1.9	○
47	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
46	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , <b>2020</b> , 136, 36-37	2.2	
45	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2	
44	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , <b>2021</b> , 138, 1327-1327	2.2	
43	T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 3522-3522	2.2	
42	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 1439-1439	2.2	
41	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , <b>2021</b> , 138, 808-808	2.2	
40	APRIL Promotes Survival and Proliferation of T Cells: Implications for T-Cell Lymphoma.. <i>Blood</i> , <b>2004</b> , 104, 2652-2652	2.2	
39	Elevated BLYS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLYS Polymorphisms.. <i>Blood</i> , <b>2004</b> , 104, 964-964	2.2	
38	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. <i>Blood</i> , <b>2004</b> , 104, 1397-1397	2.2	
37	B-Lymphocyte Stimulator (BLYS) Is Highly Expressed in Waldenstrom $\beta$ Macroglobulinemia.. <i>Blood</i> , <b>2004</b> , 104, 2291-2291	2.2	
36	Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.. <i>Blood</i> , <b>2005</b> , 106, 1495-1495	2.2	
35	Intratumoral CD4+CD25+ Regulatory T-Cell-Mediated Suppression of Infiltrating CD4+ T-Cells in B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , <b>2005</b> , 106, 3312-3312	2.2	
34	Intratumoral Treg Cells Completely Inhibit the Induction and Function of Tumor-Infiltrating CD8+ T-Cells in B-Cell NHL.. <i>Blood</i> , <b>2005</b> , 106, 3311-3311	2.2	
33	Role of CCL5 and Interleukin-6 in the Biology of Waldenstro m Macroglobulinemia.. <i>Blood</i> , <b>2007</b> , 110, 688-688	2.2	
32	Malignant B Cells Skew the Balance between Treg Cell and TH17 Cell Differentiation in B-Cell Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , <b>2007</b> , 110, 1347-1347	2.2	

- 31 Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 622-622.2
- 30 Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). *Blood*, **2018**, 132, 4138-4138 2.2
- 29 A Role for TNF- $\alpha$  in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. *Blood*, **2019**, 134, 4276-4276 2.2
- 28 Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. *Blood*, **2019**, 134, 2774-2774 2.2
- 27 Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. *Blood*, **2019**, 134, 2764-2764 2.2
- 26 Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. *Blood*, **2019**, 134, 919-919 2.2
- 25 Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. *Blood*, **2019**, 134, 923-923 2.2
- 24 Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. *Blood*, **2019**, 134, 2790-2790 2.2
- 23 Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile.. *Journal of Clinical Oncology*, **2020**, 38, 8052-8052 2.2
- 22 An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.. *Journal of Clinical Oncology*, **2014**, 32, e22171-e22171 2.2
- 21 Presence and function of CD14+CD16-HLADR<sup>low</sup> monocytes in the peripheral blood of patients with B-cell non-Hodgkin lymphoma (NHL).. *Journal of Clinical Oncology*, **2014**, 32, e19539-e19539 2.2
- 20 Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. *Blood*, **2015**, 126, 131-131 2.2
- 19 Signal-Regulatory Protein- $\alpha$  (SIRP- $\alpha$ ) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. *Blood*, **2016**, 128, 2515-2515 2.2
- 18 Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. *Blood*, **2016**, 128, 2935-2935 2.2
- 17 Isogenic Loss of TNFAIP3 in Waldenstrom Macroglobulinemia Enhances MYD88L265P-Driven Signaling. *Blood*, **2016**, 128, 4100-4100 2.2
- 16 Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. *Blood*, **2009**, 114, 440-440 2.2
- 15 Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.. *Blood*, **2009**, 114, 3927-3927 2.2
- 14 A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. *Blood*, **2010**, 116, 1999-1999 2.2

- 13 Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. *Blood*, **2010**, 116, 991-991 2.2
- 12 A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. *Blood*, **2010**, 116, 468-468 2.2
- 11 Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. *Blood*, **2010**, 116, 3115-3115 2.2
- 10 A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. *Blood*, **2010**, 116, 143-143 2.2
- 9 Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. *Blood*, **2011**, 118, 1570-1570 2.2
- 8 Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. *Blood*, **2011**, 118, 429-429 2.2
- 7 IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. *Blood*, **2011**, 118, 770-770 2.2
- 6 A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. *Blood*, **2011**, 118, 2642-2642 2.2
- 5 Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.. *Blood*, **2012**, 120, 2688-2688 2.2
- 4 Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. *Blood*, **2012**, 120, 149-149 2.2
- 3 Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. *Blood*, **2012**, 120, 1563-1563 2.2
- 2 IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia. *Blood*, **2012**, 120, 1554-1554 2.2
- 1 CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. *Blood*, **2012**, 120, 2702-2702 2.2